|Cell phone number with international prefix: +30.6937.300.301|
|Affiliation: Dept. of Chemistry, University of Patras, Patras, Greece|
|Gender: F □ M □X|
|Year of the PhD title: 2003|
|Personal web page: http://|
|Previous COST participation: No □ Yes □ X|
List of 10 selected publications within last 5 years
|1. S.Stoica, A. I. Antoniou, S.Suleiman, A. Cassar, L. Gatt, D. Papaioannou, C. M. Athanassopoulos*,
P. Schembri-Wismayer* Bioorganic & Medicinal Chemistry Letters 2016, 26, 1145-1150.
|2. S.E. Bariamis, G.E. Magoulas, K. Grafanaki, E. Pontiki, T. Tsegenidis, C.M. Athanassopoulos,
D. Papaioannou, and D. Hadjipavlou-Litina Bioorganic & Medicinal Chemistry, 2015 , 23, 7251-7263.
|3. G.E. Magoulas, O.N. Kostopoulou, C.M. Athanassopoulos, T. Garnelis, G.G. Kournoutou,
M. Leotsinidis, G.P. Dinos, D. Papaioannou, D.L. Kalpaxis, Bioorganic & Medicinal Chemistry, 2015, 23, 3163-3174.
|4. D. Hadjipavlou-Litina, G.E. Magoulas, S.E. Bariamis, Z. Tsimali, K. Avgoustakis, C.A. Kontogiorgis,
C.M. Athanassopoulos and Dionissios Papaioannou, Biochimie, 2013, 95, 1437–1449.
|5. Vourtsis D, Giannou T., Sadikoglou E., Theodorakopoulou O., Sarrou H., Magoulas G.,
Athanassopoulos CM, Drainas D., Papaioannou D. and Papadimitriou E., Eur J Pharmacol, 2013, 698, 122–130.
|6. E. Bariamis, M. Marin, C. M. Athanassopoulos, C. Kontogiorgis, Z. Tsimali, D. Papaioannou,
Sindona, G. Romeo, K. Avgoustakis and D. Hadjipavlou-Litina, European Journal of Medicinal Chemistry, 2013, 60, 155-169.
|7. G.E Magoulas, T. Garnelis, C. M. Athanassopoulos, D. Papaioannou, G. Mattheolabakis,
K. Avgoustakis, D. Hadjipavlou-Litina, Tetrahedron, 2012, 68, 7041-7049.
|8. G.E. Magoulas, S.E. Bariamis, C.M Athanassopoulos, A. Haskopoulos, P.Dedes, M. Krokidis,
N.K. Karamanos, D. Kletsas, D. Papaioannou, G. Maroulis, European Journal of Medicinal Chemistry, 2011, 46, 721-737.
|9. G.E. Magoulas, S.E. Bariamis, C.M. Athanassopoulos, D. Papaioannou, Tetrahedron Letters, 2010,
Main skills and expertise (up to 5)
|1. Synthetic Organic Chemistry|
|2. Medicinal Chemistry|
|3. Anticancer Agents|
|5. Amino acid, Retinoid, Psoralen and Polyamine Synthesis|
Main equipment/facilities available in the participants’ lab (up to 5)
|1. Facilities for Organic Synthesis|
|2. HPLC for purifications|
|3. ESI-MS for routine MS spectra|
|4. NMR (400 and 600 MHz full access to the common platform instrumental analysis lab)|
|5. MALDI-TOF/TOF HRMS and ESI-ion trap MS (full access to the common platform instrumental analysis lab)|
Short personal activity proposal for the COST Action CA15135 (max 1000 characters)
|In my opinion for the best and fast networking and collaboration kick-off within the members and WGs we should think of establishing a compound library to which the WG1 members should provide new samples (at the beginning even already out of the self) and members from WG2 will evaluate against new targets. This work is essential for the successful complimentary collaboration of the other two WGs (WG3 and WG4).
The establishment of the compound library will work as an ice-breaker and will facilitate the fast and productive collaboration between members of different disciplines, which is main aim of COST Actions in general.
My contribution to the action according the above described framed can be summarized as follows:
· Help for the establishment of the compound library if all agree on that.
· Provide samples for the library (mainly antiproliferative, antibacterial and antipsoriatic agents).
· Development and synthesis of new chemical entities targeting special targets, in collaboration with colleagues from WG2 and WG4.
Work Group preference: score from 1 (preferred) to 4 (not preferred)
|Work Group of the CA15135 COST Action||Score|
|WG1: Development of new chemical entities||1|
|WG2: Selection of biological targets and assessment of biological data||4|
|WG3: Development of chemical databases||4|
|WG4: Development of Computational methods for multiple ligand design and discovery||4|